Carlyle Group Inc. increased its position in shares of Exicure, Inc. (NASDAQ:XCUR - Free Report) by 400.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 281,636 shares of the company's stock after acquiring an additional 225,308 shares during the period. Exicure comprises approximately 0.9% of Carlyle Group Inc.'s portfolio, making the stock its 11th biggest holding. Carlyle Group Inc. owned about 10.79% of Exicure worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Geode Capital Management LLC bought a new stake in Exicure in the 4th quarter valued at $173,000. 42.82% of the stock is owned by hedge funds and other institutional investors.
Exicure Stock Performance
Shares of NASDAQ:XCUR traded down $3.11 on Friday, hitting $8.44. 63,918 shares of the company were exchanged, compared to its average volume of 571,358. Exicure, Inc. has a one year low of $1.44 and a one year high of $36.00. The firm has a market capitalization of $53.32 million, a price-to-earnings ratio of -4.08 and a beta of 3.74. The company's 50 day moving average price is $11.27 and its two-hundred day moving average price is $10.91.
Exicure (NASDAQ:XCUR - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.
Exicure Profile
(
Free Report)
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
Featured Articles
Before you consider Exicure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exicure wasn't on the list.
While Exicure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
